ArticleJournal of lower genital tract disease2016
Clinical Performance Validation of 4 Point-of-Care Cervical Cancer Screening Tests in HIV-Infected Women in Zambia.
Article in Journal of lower genital tract disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.Systematic reviews · 2018Pooled it
- Integrating Human Papillomavirus and HIV Services Into a One-Stop Breast Cancer Early Detection Clinic in Zambia.JCO global oncology · 2026Article
- Prevalence and predictors of cervical lesions among women on ART in the Awi Zone, Northwest Ethiopia: facility-based cross-sectional study.BMC women's health · 2025Article
- Mapping the cancer research landscape across Zambia: evidence to support national cancer control planning.Ecancermedicalscience · 2025Review
- Entangled Connections: HIV and HPV Interplay in Cervical Cancer-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, Zambia.BMJ oncology · 2024Article
- Validation in Zambia of a cervical screening strategy including HPV genotyping and artificial intelligence (AI)-based automated visual evaluation.Infectious agents and cancer · 2023Article
- Digital cervicography for cervical cancer screening in low-resource settings: A scoping review.Gynecologic oncology reports · 2023Article
- Performance of screening tools for cervical neoplasia among women in low- and middle-income countries: A systematic review and meta-analysis.PLOS global public health · 2023Article
- Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- A novel cervical cancer screen-triage-treat demonstration project with HPV self-testing and thermal ablation for women in Malawi: Protocol for a single-arm prospective trial.Contemporary clinical trials communications · 2022Article
- Utilisation of cervical cancer screening among women living with HIV at Kenya's national referral hospital.Southern African journal of HIV medicine · 2022Article
- Article
- Cervical cancer prevention and control in women living with human immunodeficiency virus.CA: a cancer journal for clinicians · 2021Review
- Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.PLoS medicine · 2021Article
- Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol.BMJ open · 2020Article
- Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women.Cancer medicine · 2020Article
- Development of Low-Cost Point-of-Care Technologies for Cervical Cancer Prevention Based on a Single-Board Computer.IEEE journal of translational engineering in health and medicine · 2020Article
- Performance of vaginal self-sampling for human papillomavirus testing among women living with HIV in Botswana.International journal of STD & AIDS · 2019Article
- Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus.Obstetrics and gynecology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesWe sought to determine the clinical performance of visual inspection with acetic acid (VIA), digital cervicography (DC), Xpert human papillomavirus (HPV), and OncoE6 for cervical cancer screening in an HIV-infected population. MATERIALS AND
methodsHIV-infected women 18 years or older were included in this cross-sectional validation study conducted in Lusaka, Zambia. The screening tests were compared against a histological gold standard. We calculated sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and odds ratios using cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+) thresholds.
resultsBetween January and June 2015, a total of 200 women were enrolled. Fifteen percent were screen positive by VIA, 20% by DC, 47% by Xpert HPV, and 6% by OncoE6. Using a CIN 2+ threshold, the sensitivity and specificity of VIA were 48% (95% CI = 30%-67%) and 92% (95% CI = 86%-95%), respectively. Similarly, the sensitivity and specificity of DC were 59% (95% CI = 41%-76%) and 88% (95% CI = 82%-93%), respectively. The sensitivity and specificity of Xpert HPV were 88% (95% CI = 71%-97%) and 60% (95% CI = 52%-68%), respectively. Finally, the sensitivity and specificity of OncoE6 were 31% (95% CI = 16%-50%) and 99% (95% CI = 97%-100%), respectively.
conclusionsVIA and DC displayed moderate sensitivity and high specificity. Xpert HPV performed equivalently to currently approved HPV DNA tests, with high sensitivity and moderate specificity. OncoE6 displayed excellent specificity but low sensitivity. These results confirm an important role for VIA, DC, and Xpert HPV in screen-and-treat cervical cancer prevention in low- and middle-income countries, such as Zambia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.